

Drug Utilization Review Board Meeting Minutes
September 23, 2015

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members Present:

Lester Labus, MD, Chair
Kc Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Christopher Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Michel Lonsinger, PharmD
Ernest Miller, DO (via phone)
Mary Nemeth-Pyles, MSN, RN, CS
Chris Terpening, PharmD, PhD
John Vanin, MD

Members Absent:

Myra Chiang, MD
Karen Fitzpatrick, MD
Pat Regan, PharmD

DHHR/BMS Staff Present:

Brian Thompson, MS, PharmD, DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff:

Steve Small, M.S., RPh, Rational Drug Therapy Program (RDTP)
Scott House, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Steve Liles, PharmD, Goold Health Systems / Emdeon

- I. **INTRODUCTIONS** - Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting (16:09). The DUR board and attendees introduced themselves. A motion was made, seconded and approved to accept the minutes from the previous DUR Board meeting.

- II. **OLD BUSINESS**
 - A. None

- III. **NEW BUSINESS**
 - A. **Speakers: 4 speakers**
 - 1 Ndidi Yaucher - Novartis– Cosentyx
 - 2 Amit Duggal – Bristol Myers Squibb – Daklinza
 - 3 Kristi Cavaliere – Amgen - Corlanor

- 4 Mark Demary – Coventry Care (Medicaid MCO) – Long-acting Opioid Analgesic criteria
- 5 Raheel Khan – Cystic Fibrosis Foundation - Orkambi

B. Updates from August 26, 2015 P&T Committee Meeting:

- 1 Dr. Labus reviewed the changes from the P&T meeting, and a motion was made, seconded and approved to accept the suggested changes.
Attachment A

C. Prior Authorization Criteria

- 1 Class Criteria – Analgesics, narcotic long acting – Motion to approve was made, seconded and passed with the following change: Add criteria stating: If no generic form is available for the requested non-preferred brand agent, then another generic non-preferred agent must be trialed instead.
- 2 Class Criteria – Cytokine and CAM Antagonists - Motion to approve was made, seconded and passed.
- 3 Class Criteria – Liptropics, others (non-statins), Fatty Acids sub-class: Motion to approve was made, seconded and passed with the following change: Add criteria to all non-preferred agents stating that a minimum starting triglyceride level of 500 or greater is required for coverage.
- 4 Evzio – Motion to approve was made, seconded and passed with the following change: Change the requirement that the prescriber **must** complete the Opioid Overdose Risk Assessment Checklist form, to a recommendation that the prescriber complete the checklist.
- 5 Humira (new indication) - Motion to approve was made, seconded and passed.
- 6 Corlanor- Motion to approve was made, seconded and passed with the following change: Remove denial criteria of a resting heart rate of less than 60 bpm prior to treatment.
- 7 Cosentyx - Motion to approve was made, seconded and passed.
- 8 Daklinza - Motion to approve was made, seconded and passed.
- 9 Invega Trinza - Motion to approve was made, seconded and passed.
- 10 Myalept - Motion to approve was made, seconded and passed.
- 11 Orkambi - Motion to approve was made, seconded and passed
- 12 Praluent - Motion to approve was made, seconded and passed.
- 13 Relistor - Motion to approve was made, seconded and passed.
- 14 Technivie - Motion to approve was made, seconded and passed with the following change: Add to Duration of approval that Technivie will only be approvable in combination with ribavirin as a 12-week regimen for the treatment of non-cirrhotic GT - 4 HCV infections.
- 15 Xifaxin - Motion to approve was made, seconded and passed.
Attachment B

IV. **REPORTS**

- A. **Molina Quarterly Report –Second Quarter 2015** - Eric Sears gave an overview of the Molina 2015 Second Quarter Report. The presentation included a review of the DUR Quarterly Overall Summary Report.
See Attachment C
- B. **Rational Drug Therapy Program** - Steve Small gave a slide presentation overview of the program activities for the Second quarter.
See Attachment D

VI. **OTHER BUSINESS - OPEN TO THE FLOOR**

- A. None

VII. **NEXT MEETING AND ADJOURNMENT**

- A. A motion was made, seconded and approved to adjourn the meeting.
- B. The meeting concluded at 6:10 p.m.
- C. The next meeting will be Wednesday, November 18, 2015 from 4:00 PM-6:00 PM located at the WVDHHR.

Submitted by:

Brian M. Thompson, PharmD